APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing

doi:10.1007/s12072-016-9736-3

Review

. 2016 Sep;10(5):681-701.

doi: 10.1007/s12072-016-9736-3. Epub 2016 May 26.

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing

Masao Omata^{1

2}, Tatsuo Kanda³, Lai Wei⁴, Ming-Lung Yu⁵, Wang-Long Chuang⁶, Alaaeldin Ibrahim⁷, Cosmas Rinaldi Adithya Lesmana⁸, Jose Sollano⁹, Manoj Kumar¹⁰, Ankur Jindal¹⁰, Barjesh Chander Sharma¹¹, Saeed S Hamid¹², A Kadir Dokmeci¹³, Mamun Al-Mahtab¹⁴, Geofferey W McCaughan¹⁵, Jafri Wasim¹², Darrell H G Crawford¹⁶, Jia-Horng Kao¹⁷, Osamu Yokosuka³, George K K Lau¹⁸, Shiv Kumar Sarin¹⁰

Affiliations

¹ Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu-shi, Yamanashi, 400-8506, Japan. momata-tky@umin.ac.jp.
² The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. momata-tky@umin.ac.jp.
³ Graduate School of Medicine, Chiba University, Chiba, Japan.
⁴ Peking University People's Hospital, Peking University Hepatology Institute, Beijing, China.
⁵ Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
⁶ Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
⁷ GI/Liver Division, Department of Internal Medicine, University of Benha, Banha, Egypt.
⁸ Digestive Disease and GI Oncology Center, Medistra Hospital, University of Indonesia, Jakarta, Indonesia.
⁹ University Santo Tomas Hospital, Manila, Philippines.
¹⁰ Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
¹¹ Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India.
¹² Department of Medicine, Aga Khan University and Hospital, Stadium Road, Karachi, 74800, Pakistan.
¹³ Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey.
¹⁴ Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh.
¹⁵ Royal Prince Alfred Hospital, Centenary Institute, University of Sydney, Sydney, Australia.
¹⁶ University of Queensland, School of Medicine, Woolloongabba, QLD, 4102, Australia.
¹⁷ National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan.
¹⁸ The Institute of Translational Hepatology, Beijing 302 Hospital, Beijing, China.

PMID: 27229718
PMCID: PMC5003900
DOI: 10.1007/s12072-016-9736-3

Review

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing

Masao Omata et al. Hepatol Int. 2016 Sep.

. 2016 Sep;10(5):681-701.

doi: 10.1007/s12072-016-9736-3. Epub 2016 May 26.

Authors

Affiliations

¹ Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu-shi, Yamanashi, 400-8506, Japan. momata-tky@umin.ac.jp.
² The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. momata-tky@umin.ac.jp.
³ Graduate School of Medicine, Chiba University, Chiba, Japan.
⁴ Peking University People's Hospital, Peking University Hepatology Institute, Beijing, China.
⁵ Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
⁶ Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
⁷ GI/Liver Division, Department of Internal Medicine, University of Benha, Banha, Egypt.
⁸ Digestive Disease and GI Oncology Center, Medistra Hospital, University of Indonesia, Jakarta, Indonesia.
⁹ University Santo Tomas Hospital, Manila, Philippines.
¹⁰ Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
¹¹ Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India.
¹² Department of Medicine, Aga Khan University and Hospital, Stadium Road, Karachi, 74800, Pakistan.
¹³ Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey.
¹⁴ Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh.
¹⁵ Royal Prince Alfred Hospital, Centenary Institute, University of Sydney, Sydney, Australia.
¹⁶ University of Queensland, School of Medicine, Woolloongabba, QLD, 4102, Australia.
¹⁷ National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan.
¹⁸ The Institute of Translational Hepatology, Beijing 302 Hospital, Beijing, China.

PMID: 27229718
PMCID: PMC5003900
DOI: 10.1007/s12072-016-9736-3

Abstract

The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on "APASL consensus statements and recommendations for management of hepatitis C" in March 2015 to revise the "APASL consensus statements and management algorithms for hepatitis C virus infection" (Hepatol Int 6:409-435, 2012). The working party consisted of expert hepatologists from the Asian-Pacific region gathered at the Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed, and debated during the course of drafting a revision. Participants of the consensus meeting assessed the quality of the cited studies. The finalized recommendations for hepatitis C prevention, epidemiology, and laboratory testing are presented in this review.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standards All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki 1975, as revised in 2008 (5). Informed consent was obtained from all patients included in the study. This article does not contain any studies with animal subjects. Conflict of interest Alaaeldin Ibrahim, Cosmas Rinaldi Adithya Lesmana, Mamun Al-Mahtab, George K. K. Lau, Barjesh C. Sharma, Jose Sollano, Manoj Kumar, Ankur Jindal, A. Kadir Dokmeci, Geofferey W. McCaughan, Darrell H. G. Crawford, Jafri Wasim, and Shiv Kumar Sarin declare that they have no conflict of interest. Masao Omata received fees for being a speaker, consultant, and advisory board member for Bayer Co., Boehringer Ingelheim, Bristol-Myers Squibb, Otsuka, Astellas, Gilead Sciences, Chugai, Mitsubishi Tanabe, Kyorin, Merck Sharp & Dohme, Dainippon Sumitomo, Vertex Pharmaceuticals, Takeda, and Zeria. Tatsuo Kanda received lecture fees from Chugai Pharmaceutical, MSD, Tanabe-Mitsubishi, Daiichi-Sankyo, Bristol-Myers Squibb, Gilead Sciences, and AbbVie and a research grant from Chugai and MSD. Lai Wei has research grants from BMS and Roche and received consulting fees from Abbott, AbbVie, BMS, Gilead, and Novartis. Ming-Lung Yu is a consultant and advisory board member and has grant support from AbbVie, BMS, Gilead, Roche, MSD, and Abbott. Wang-Long Chuang received speaker fees from Gilead, BMS, MSD, Roche, and Novartis and is a member of the following advisory boards: Gilead, AbbVie, and Roche. Saeed S. Hamid has conference travel support from Gilead. Jia-Horng Kao has served as a consultant for AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Roche and has also served on speakers’ bureaus for Roche, Bristol-Myers Squibb, Gilead Sciences, and Novartis. Osamu Yokosuka has research grants from Chugai Pharmaceutical, Bayer, MSD, Daiichi-Sankyo, Tanabe-Mitsubishi, and Bristol-Myers Squibb and received speaking fees from Merck Sharp and Dohme, Kowa Souku, Sysmex, Chugai Pharmaceutical Co., GlaxoSmithKline, Bristol-Myers Squibb, Ajinomoto-Seiyaku, Bayer, Abbott, Given Imaging, Mitsubishi Tanabe Pharm, Taiho Yakuhin, Dainippon Sumitomo Pharm, and Igaku-Seibutsugaku Institute.

Cited by

2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.
Korean Association for the Study of the Liver (KASL). Korean Association for the Study of the Liver (KASL). Clin Mol Hepatol. 2018 Sep;24(3):169-229. doi: 10.3350/cmh.2018.1004. Epub 2018 Aug 10. Clin Mol Hepatol. 2018. PMID: 30092624 Free PMC article. Review. No abstract available.
Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting.
Blanco-Grau A, Gabriel-Medina P, Rodriguez-Algarra F, Villena Y, Lopez-Martínez R, Augustín S, Pons M, Cruz LM, Rando-Segura A, Enfedaque B, Riveiro M, Casis E, Ferrer-Costa R, Buti M, Rodriguez-Frias F. Blanco-Grau A, et al. Diagnostics (Basel). 2021 Nov 29;11(12):2236. doi: 10.3390/diagnostics11122236. Diagnostics (Basel). 2021. PMID: 34943471 Free PMC article.
Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines.
Malik F, Bailey H, Chan P, Collins IJ, Mozalevskis A, Thorne C, Easterbrook P. Malik F, et al. JHEP Rep. 2021 Jan 15;3(2):100227. doi: 10.1016/j.jhepr.2021.100227. eCollection 2021 Apr. JHEP Rep. 2021. PMID: 33665586 Free PMC article.
Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia.
Byambasuren A, Gyarvuulkhasuren B, Erdenebat B, Nyamdavaa K, Baatarkhuu O. Byambasuren A, et al. Viruses. 2025 May 22;17(6):743. doi: 10.3390/v17060743. Viruses. 2025. PMID: 40573334 Free PMC article.
The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment.
Choi J, Park J, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Chung YH. Choi J, et al. Gut Liver. 2022 Nov 15;16(6):964-975. doi: 10.5009/gnl210416. Epub 2022 Mar 31. Gut Liver. 2022. PMID: 35354688 Free PMC article.

See all "Cited by" articles

References

1. Omata M, Kanda T, Yokosuka O, Crawford D, Al-Mahtab M, Wei L, et al. Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. Hepatol Int 2015;9:486–507 - PubMed
1. Zheng X, Ding W, Li G, Wu Y, Wu D, Zhu H, He J, Wang B, Zhao L, Zhu F, Lv H. Seroprevalence of transfusion-transmissible infectious agents among volunteer blood donors between 2006 and 2012 in Zhejiang, China. Blood Transfus 2015;13:401–410 - PMC - PubMed
1. Song Y, Bian Y, Petzold M, Ung CO. Prevalence and trend of major transfusion-transmissible infections among blood donors in Western China, 2005 through 2010. PLoS One 2014;9:e94528 - PMC - PubMed
1. Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, Tateishi R, Hamid SS, Chuang WL, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao JH, McCaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409–435 - PubMed
1. Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS, Hardikar W, Hui CK, Jafri W, Jia JD, Lai MY, Wei L, Leung N, Piratvisuth T, Sarin S, Sollano J, Tateishi R. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:615–633 - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Molecular Biology Databases
- NIAID Data Ecosystem - Find datasets on Infectious and Immune-mediated Diseases

[1] Omata M, Kanda T, Yokosuka O, Crawford D, Al-Mahtab M, Wei L, et al. Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. Hepatol Int 2015;9:486–507 - PubMed

[2] Omata M, Kanda T, Yokosuka O, Crawford D, Al-Mahtab M, Wei L, et al. Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. Hepatol Int 2015;9:486–507 - PubMed

[3] Zheng X, Ding W, Li G, Wu Y, Wu D, Zhu H, He J, Wang B, Zhao L, Zhu F, Lv H. Seroprevalence of transfusion-transmissible infectious agents among volunteer blood donors between 2006 and 2012 in Zhejiang, China. Blood Transfus 2015;13:401–410 - PMC - PubMed

[4] Zheng X, Ding W, Li G, Wu Y, Wu D, Zhu H, He J, Wang B, Zhao L, Zhu F, Lv H. Seroprevalence of transfusion-transmissible infectious agents among volunteer blood donors between 2006 and 2012 in Zhejiang, China. Blood Transfus 2015;13:401–410 - PMC - PubMed

[5] Song Y, Bian Y, Petzold M, Ung CO. Prevalence and trend of major transfusion-transmissible infections among blood donors in Western China, 2005 through 2010. PLoS One 2014;9:e94528 - PMC - PubMed

[6] Song Y, Bian Y, Petzold M, Ung CO. Prevalence and trend of major transfusion-transmissible infections among blood donors in Western China, 2005 through 2010. PLoS One 2014;9:e94528 - PMC - PubMed

[7] Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, Tateishi R, Hamid SS, Chuang WL, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao JH, McCaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409–435 - PubMed

[8] Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, Tateishi R, Hamid SS, Chuang WL, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao JH, McCaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409–435 - PubMed

[9] Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS, Hardikar W, Hui CK, Jafri W, Jia JD, Lai MY, Wei L, Leung N, Piratvisuth T, Sarin S, Sollano J, Tateishi R. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:615–633 - PubMed

[10] Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS, Hardikar W, Hui CK, Jafri W, Jia JD, Lai MY, Wei L, Leung N, Piratvisuth T, Sarin S, Sollano J, Tateishi R. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:615–633 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing

Affiliations

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases